News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Giulia Tonini

Articles by Giulia Tonini

27 Elacestrant vs Standard of Care in ER+, HER2- Advanced or Metastatic Breast Cancer With ESR1-Mutated Tumors: ESR1 Allelic Frequencies and Clinical Activity From the Phase 3 EMERALD Trial

ByAditya Bardia, MD, MPH, FASCO,Javier Cortés, MD,Francois Clement Bidard,Guillermo Streich,José García-Sáenz,Janice Lu, MD, PhD ,Giulia Tonini,Simona Scartoni,Alessandro Paoli,Alessio Fiascarelli,Alessandro Bressan,Monica Binaschi,Tomer Wasserman,Virginia Kaklamani, MD, DSc

June 19th 2025

TPS 28 ELEGANT: Elacestrant VS Standard Endocrine Therapy in Women and Men With Node-Positive, Estrogen Receptor-Positive, HER2-Negative, Early Breast Cancer With High Risk of Recurrence in a Global, Multicenter, Randomized, Open-Label Phase 3 Study

ByAditya Bardia, MD, MPH, FASCO,Virginia Kaklamani, MD, DSc,Joyce A. O’Shaughnessy,Peter Schmid, MD,J. Thaddeus Beck,,Michelino De Laurentiis,Guiseppe Curigliano,Hope S. Rugo, MD,Carlos Barcenas,William J. Gradishar, MD,Michail Ignatiadis,David Cameron,Giulia Tonini,Simona Scartoni,Jennifer Crozier,Leo Viana Nicacio,Tomer Wasserman,Sara M. Tolaney, MD, MPH

June 18th 2025

9 Elacestrant (ELA) vs Standard-of-Care (SOC) in ER+/HER2–Advanced (adv) or Metastatic Breast Cancer (mBC) with ESR1 Mutation (ESR1-mut): Key Biomarkers and Clinical Subgroup Analyses From the Phase 3 EMERALD Trial

9 Elacestrant (ELA) vs Standard-of-Care (SOC) in ER+/HER2–Advanced (adv) or Metastatic Breast Cancer (mBC) with ESR1 Mutation (ESR1-mut): Key Biomarkers and Clinical Subgroup Analyses From the Phase 3 EMERALD Trial

ByAditya Bardia, MD, MPH, FASCO,Joyce O’Shaughnessy, MD,Francois Clement Bidard,Phillipe Aftimos,Javier Cortes,Janice Lu, MD, PhD ,Giulia Tonini,Kathy Puyana Theall,Alessandro Paoli,Virginia Kaklamani, MD, DSc

August 24th 2024

12 EMERALD Trial Analysis of Patient-Reported Outcomes (PROs) in Patients (pts) With ER+/HER2- Advanced or Metastatic Breast Cancer (mBC) Comparing Oral Elacestrant vs Standard-of-Care (SoC) Endocrine Therapy

12 EMERALD Trial Analysis of Patient-Reported Outcomes (PROs) in Patients (pts) With ER+/HER2- Advanced or Metastatic Breast Cancer (mBC) Comparing Oral Elacestrant vs Standard-of-Care (SoC) Endocrine Therapy

ByJavier Cortés, MD,François-Clément Bidard,Aditya Bardia, MD, MPH, FASCO,Virginia G. Kaklamani, MD, DSc,Ioanna Vlachaki,Giulia Tonini,Nassir Habboubi,Philippe Aftimos

August 17th 2024

1 Elacestrant Versus Fulvestrant or Aromatase Inhibitor in a Phase 3 Trial Evaluating Elacestrant, an Oral Selective Estrogen Receptor Degrader Versus Standard-of- Care Endocrine Monotherapy for ER+/HER2– Advanced/Metastatic Breast Cancer

ByPhilippe Aftimos,Javier Cortes,Francois Clement Bidard,Virginia Kaklamani, MD, DSc,Aditya Bardia, MD, MPH, FASCO,Alberto J. Montero, MD, MBA, CPHQ,Joo Hyuk Sohn,Giulia Tonini,Krzysztof J. Grzegorzewski,Patrick Neven, MD, PhD

April 28th 2023

26 Subgroup Analysis of Patients With No Prior Chemotherapy in EMERALD: A Phase 3 Trial Evaluating Elacestrant, an Oral Selective Estrogen Receptor Degrader (SERD), Vs Investigator’s Choice of Endocrine Monotherapy for ER+/HER2– Advanced/ Metastatic Breast Cancer (mBC)

ByVirginia Kaklamani, MD, DSc,Aditya Bardia, MD, MPH, FASCO,Phillippe Aftimos,Javier Cortes,Patrick Neven, MD, PhD,Alberto J. Montero, MD, MBA, CPHQ,Joo Hyuk Sohn,Giulia Tonini,Krzysztof J. Grzegorzewski,François-Clément Bidard

April 27th 2023

Latest Updated Articles

Trending on CancerNetwork

Atezolizumab/Vaccine Combo May Show Long-Term Survival in ES-SCLC

This Week in Oncology: FDA Approval Shakeups and Key SITC 2025 Data

PEF Ablation Yields Local Control, May Elicit Immune Response in Solid Tumors

Identifying Common Toxicities with Targeted Therapies in GI Malignancies

The Latest and Hottest Topics in ADCs: A Discussion With a Chemical Engineer

© 2025 MJH Life Sciences^®

All rights reserved.